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Objectives This study was done to compare effects of high versus standard clopidogrel maintenance doses on platelet inhi-
bition, inflammation, and endothelial function in patients undergoing percutaneous coronary intervention.
Background Previous data suggested that clopidogrel has various biological actions in addition to antiplatelet effects.
Methods Fifty patients were randomly assigned 1 month after intervention (T-0) to receive standard (75 mg/day; n  25)
or high (150 mg/day; n  25) clopidogrel maintenance dose for 30 days (until T-1); at this time-point, cross-over
was performed, and the assigned clopidogrel maintenance regimen was switched and continued for a further 30
days (until T-2). Platelet reactivity (expressed as P2Y12 reaction units by the point-of-care VerifyNow assay [Accu-
metrics, San Diego, California]), endothelial function (evaluated by flow-mediated vasodilation), and high-
sensitivity C-reactive protein levels were measured at T-0, T-1, and T-2.
Results Patients in the 150-mg/day arm had higher platelet inhibition (50  20% vs. 31  20% in the 75-mg/day
group; p  0.0001), better flow-mediated vasodilation (16.9  12.6% vs. 7.9  7.5%; p  0.0001), and lower
high-sensitivity C-reactive protein levels (3.6  3.0 mg/l vs. 7.0  8.6 mg/l; p  0.016). Higher clopidogrel dose
was associated with decreased proportion of patients with P2Y12 reaction units 240 (12% vs. 32%; p 
0.001), flow-mediated vasodilation 7% (16% vs. 58%; p  0.0003), and high-sensitivity C-reactive protein lev-
els 3 mg/l (46% vs. 64%; p  0.07).
Conclusions For patients undergoing percutaneous coronary intervention, the 150-mg/day clopidogrel maintenance dose is
associated with stronger platelet inhibition, improvement of endothelial function, and reduction of inflammation,
compared with the currently recommended 75-mg/day regimen; those effects might have a role in the clinical
benefit observed with clopidogrel and may provide the rationale for using the higher maintenance regimen in
selected patients. (J Am Coll Cardiol 2011;57:771–8) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.050A growing number of patients with coronary artery disease
receive chronic therapy with clopidogrel; as recommended,
patients with acute coronary syndromes (ACS) treated both
medically or with percutaneous coronary intervention (PCI)
receive 1 year of treatment with clopidogrel in addition to
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supported by any grant or outside sources of funding or industry sponsorship. The
authors have reported that they have no relationships to disclose.Manuscript received June 7, 2010; revised manuscript received September 21, 2010,
accepted September 27, 2010.aspirin (1,2); moreover, dual antiplatelet therapy is usually
performed for 1 month after bare-metal stent implantation
and is extended for at least 12 months after drug-eluting
stent implantation to prevent stent thrombosis (3).
Adequacy of platelet inhibition with chronic clopidogrel
therapy is a contemporary issue in patients undergoing PCI,
as interindividual variability in response to the drug has been
reported (4), and a low response may predispose to future
cardiac events (5–9). Indeed, in patients receiving the 75
mg/day clopidogrel maintenance dose, a further platelet
inhibition is achieved at short-term by giving an additive
600-mg loading dose (10) and chronically by increasing the
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spective data indicated that pa-
tients receiving the 600 mg clopi-
dogrel loading plus 150 mg
maintenance regimen 15 days af-
ter PCI may have a lower incidence
of cardiac events at 2 months (12).
Previous studies suggest that
clopidogrel has anti-inflammatory
effects (13,14) and improves endo-
thelial function (15), but no ran-
domized study has addressed the
issue of whether a higher clopi-
dogrel maintenance dose exerts, in
addition to stronger platelet inhi-
bition, a more intense anti-inflammatory effect and is associ-
ated with improved endothelial function versus the standard
regimen. Thus, this randomized, prospective study was de-
signed to compare the effectiveness of 75 mg/day versus 150
mg/day clopidogrel maintenance doses on platelet function
inhibition, inflammation, and endothelium-dependent vasodi-
lation in patients undergoing PCI.
Methods
Study population and design. The ARMYDA-150 (An-
tiplatelet Therapy for Reduction of Myocardial Damage
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
FMD  flow-mediated
dilation
hsCRP  high-sensitivity
C-reactive protein
NMD  nitroglycerin-
mediated dilation
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction
units
Figure 1 The ARMYDA-150 Study Design
ARMYDA  Antiplatelet Therapy for Reduction of Myocardial Damage During Angio
NMD  nitroglycerin-mediated dilation; PCI  percutaneous coronary intervention;During Angioplasty) study is a prospective, randomized,
single-center study with cross-over, performed on 50 con-
secutive patients receiving PCI and stent implantation for
stable angina or non–ST-segment elevation ACS. Exclu-
sion criteria were as follows: primary intervention for
ST-segment elevation myocardial infarction; platelet count
70  109/l; active bleeding or bleeding diathesis; gastro-
intestinal bleeding 6 months; cerebrovascular accident3
months; history of malignancy; concomitant need for oral
anticoagulant therapy; and severe liver disease or chronic
renal failure (serum creatinine 2 mg/dl). Active smokers
were also excluded by protocol.
All patients received 600-mg clopidogrel load before PCI
(16) and continued, after the procedure, the standard 75
mg/day clopidogrel maintenance dose for 1 month; at this
study point (T-0), patients were randomly allocated to
receive standard (1 75-mg tablet; n  25) or high (150 mg,
2 75-mg tablets; n  25) clopidogrel daily maintenance
dose for 30 days (until T-1, i.e., 2 months after PCI) (Fig. 1). At
this point, a cross-over was performed, and patients ran-
domly allocated to the 75 mg daily dose were switched to
the 150-mg daily dose and vice versa for an additional 30
days (until 3 months after the procedure, T-2). All patients
were maintained on aspirin (100 mg/day). To avoid poten-
tial interference of concomitant drugs with antiplatelet
effect of clopidogrel, during the study period, all patients
received an hydrophilic statin (pravastatin) (17) and were
FMD  flow-mediated dilation; hsCRP  high-sensitivity C-reactive protein;
P2Y reaction units.plasty;
PRU  12
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indication for gastric protection, ranitidine was used.) Pa-
tients who underwent PCI for ACS or received drug-
eluting stents continued standard clopidogrel (75 mg/day)
for 1 year after study completion.
To assign patients to standard or high clopidogrel main-
tenance dose, a computer-based randomization system was
obtained by a statistician not involved in the study; random-
ization assignment for each patient was kept in a sealed
envelope, which was opened by a trial investigator at the
study point T-0.
By protocol, at each time point (T-0, T-1, and T-2) all
patients underwent measurement of residual platelet reac-
tivity, noninvasive evaluation of endothelial function, and
testing for high-sensitivity C-reactive protein (hsCRP) level
detection; investigators performing all those measurements
were not aware of the randomization assignment.
Platelet reactivity detection. Platelet reactivity was evalu-
ted by the VerifyNow P2Y12 assay (Accumetrics, San
iego, California), which is a point-of-care assay specifi-
ally measuring direct inhibition of clopidogrel on the
latelet P2Y12 receptor. Technical details of the assay were
previously described (19). The VerifyNow reports 2 mea-
sures for each assay: 1) P2Y12 reaction units (PRU), which
eflect the extent of adenosine diphosphate-mediated aggre-
ation specific to the P2Y12 receptor and are based on the
mount of platelet aggregation in the adenosine diphos-
hate channel (the lower the PRU value, the greater the
egree of P2Y12 receptor inhibition by clopidogrel and vice
versa); and 2) percent inhibition, which represents the
percent change from baseline aggregation, and is obtained
from PRU results and the base result (the latter is an
independent measurement calculated as a function of the
amount of platelet aggregation in the thrombin receptor
activating peptide). Previous studies (5,20,21) identified, in
patients receiving clopidogrel, a PRU value 240 as the
optimal cut-off point to predict 30-day outcome after PCI;
in particular, patients with impaired clopidogrel response,
namely, with PRU above this threshold, had a 6-fold higher
risk of adverse cardiac events (5).
Measurement of brachial artery reactivity and hsCRP
levels. Noninvasive evaluation of endothelial function was
performed by ultrasound detection of brachial artery diam-
eter variations during hyperemia. All vasoactive agents were
discontinued at least 48 h before this measurement. Since
circadian variations of peripheral vascular tone occur (22),
assessment of brachial artery vasomotion was done between
9:00 AM and 9:30 AM in a quiet, temperature-controlled
oom (22°C to 24°C). Ultrasound evaluation was obtained
n the dominant forearm with the patient supine. Patients
ere kept fasting and at rest for 5 min before, and beverages
ontaining alcohol or caffeine were prohibited within the
receding 12 h. Two-dimensional brachial artery imaging
nd measurements were performed in all patients by the
ame operator, with a 7.5 MHz linear array transducer
onnected to a Hewlett Packard ultrasound machine (Sonos h500, Andover, Massachusetts); straight segments of the
rtery, 8 to 10 mm in length, were identified above the
ntecubital fossa, perpendicular to the ultrasound beam and
long its long axis. Flow-mediated dilation (FMD) due to
hear-induced endothelial nitric oxide release was evaluated
fter occlusion of the forearm circulation: 1) a longitudinal
mage was selected to calculate brachial artery diameter (first
aseline value); 2) a blood pressure cuff was inflated on the
pper arm to 50 mm Hg above the systolic pressure for 5
in and then deflated; and 3) after 1 min, a second
ongitudinal scan was obtained, and brachial artery diameter
as measured (post-occlusion value). The FMD was ex-
ressed as percent diameter variation (absolute diameter
hanges were also recorded). After 15 min of rest, a new
etection of brachial artery diameter was done (second
aseline value) and repeated 3 min after administration of
.5 mg sublingual nitroglycerin (post-nitrates value).
ndothelium-independent dilation (nitroglycerin-mediated
ilation [NMD]), due to direct effect of nitroglycerin-
erived nitric oxide, was then obtained and expressed as
ercent diameter variation. All brachial artery diameters
ere measured from near-to-far blood-wall interface
intima-media interfaces); measurements were performed at
nd-diastole in the cardiac cycle (onset of the R-wave), by
lectrocardiogram gating during image acquisition. Five
ardiac cycles were analyzed and averaged for each scan. In
previous prospective study (23) performed by our study
roup on patients undergoing PCI with bare-metal stent
mplantation, an impaired endothelial function, identified
y FMD7%, was associated with a 4.5-fold increased risk
f in-stent restenosis during follow-up, whereas FMD7%
ad a negative predictive value of 96% for excluding
estenosis.
The hsCRP was assayed by the KRIPTOR-ultrasensitive
mmunofluorescent assay (BRAHMS, Hennigsdorf/Berlin,
ermany), with a detection limit of 0.06 mg/l; 90% of normal
alues for CRP is 3 mg/l, and consistent with previous
ecommendations from the Centers for Disease Control and
revention, this cut-off point for CRP was used to differentiate
atients at higher versus lower inflammatory status (24).
nd points. Clinical follow-up was obtained in all pa-
ients at study points T-0, T-1, and T-2 by office visit.
ncidence of adverse cardiovascular events, including stent
hrombosis and bleeding complications were recorded, as
ell as of drug-related side effects. Each patient gave written
nformed consent to the study. Study end points were
omparisons in the 2 arms (75 mg/day vs. 150 mg/day
lopidogrel maintenance dose) of the following parameters:
latelet reactivity: 1) absolute PRU values; 2) percent
nhibition in PRU values from estimated baseline; and 3)
ercentage of patients with absolute PRU values 240.
rachial artery reactivity: 1) percent FMD values; 2) inci-
ence of patients with FMD 7%; and 3) percent NMD
alues. Inflammation: 1) absolute hsCRP values; and 2)
sCRP variations across study time points.
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High Versus Standard Clopidogrel Maintenance in PCI February 15, 2011:771–8Statistics. In the ARMYDA-PRO (Antiplatelet Therapy
for Reduction of Myocardial Damage During Angioplasty–
Platelet Reactivity Predicts Outcome) study (5), the inci-
dence of clopidogrel low-responders, defined by patients
with PRU values 240, was 30%; if we expect a similar
percentage of low-responders in the 75-mg/day arm and
hypothesize a relative reduction of low-responders with the
150 mg regimen similar to that reported in a recent
randomized study with the vasodilator-stimulated phospho-
protein assay (74%) (25), considering the cross-over design,
a sample size of 48 patients would provide a80% power to
detect a difference in low-responders with an alpha (p value)
of 0.05.
For the comparison of clinical and procedural features
(Table 1) between the 2 arms, the t test was used for
ormally distributed continuous values (as detected by
olmogorov-Smirnov test) and the Mann-Whitney U
est for not normally distributed variables, whereas pro-
ortions were compared by the Fisher exact test when the
xpected frequency was 5; otherwise, the chi-square
est was applied. Comparisons between the 75- and
50-mg doses for PRU values, FMD, NMD, and hsCRP
evels were performed using the Wilcoxon matched-pairs
est for continuous variables and the McNemar test for
roportions (in particular, for the comparison of patients
ith PRU 240, FMD 7%, and hsCRP 3 mg/l).
ossible interactions between 75- and 150-mg daily
oses and the 2 arms of the study (75 mg first vs. 150 mg
rst) were excluded by 2-way analysis of variance. Cor-
elations were determined by the Spearman’s rank test.
esults are indicated as mean  SD. All p values 0.05
2-tailed) were considered significant. Analysis was done
Main Features in the 2 ArmsTable 1 Main Features in the 2 Arms
Characteristics
150 Followed by
(n  2
Age, yrs 60.8 7
Male 21 (84
Diabetes mellitus 11 (44
Systemic hypertension 23 (92
Hypercholesterolemia 21 (84
Body mass index 30.3
Previous myocardial infarction 12 (48
Previous coronary intervention 12 (48
Unstable angina/NSTEMI 10 (40
Left ventricular ejection fraction, % 57.0 5
Serum creatinine, mg/dl 0.83 0
Multivessel coronary disease 11 (44
Multivessel intervention 4 (16
DES implantation 16 (64
Medical therapy
Aspirin 25 (10
Statin therapy (pravastatin) 25 (10
Proton pump inhibitors —
Values are given as mean  SD or n (%).
DES  drug-eluting stent(s); NSTEMI  non–ST-segment elevation mith SPSS 12.0 software (SPSS Inc., Chicago, Illinois).esults
he main characteristics of the study group are shown in
able 1, and were similar in patients randomized initially to
igh versus standard clopidogrel dose. During the study
eriod, no patient had adverse cardiovascular events (death,
yocardial infarction, stent thrombosis, repeat revascular-
zation, stroke) or bleeding complications; 1 patient in the
50-mg arm reported diarrhea as a side effect, but it occurred
t the end of the treatment period, which was nevertheless
ompleted. No patient was lost during study follow-up.
latelet reactivity. Absolute PRU values at the end of the
tudy drug assignment period were significantly lower with
he 150 mg dose (141  73 vs. 198  71 with 75 mg; p 
.004) (Table 2), and percent inhibition in PRU values from
stimated baseline was higher (50  20% vs. 31  20%;
p  0.0001); percentage of patients with absolute PRU
values 240 was also lower in the high-dose group (12%
vs. 32%, p  0.001; 95% confidence interval of this
difference was between 12% and 42%) (Figs. 2 and 3).
Brachial artery reactivity. After 1 month of high clopi-
dogrel maintenance dose FMD was improved (16.9 
12.6% vs. 7.9 7.5% in the standard dose arm; p 0.0001)
(Table 2), and incidence of impaired brachial artery reac-
tivity (FMD 7%) was lower (16% vs. 58%, p  0.0003;
95% confidence interval of this difference: 20% to 60%)
(Figs. 2 and 3). The NMD was also higher in patients of the
150 mg group (18.2  17.3% vs. 12.0  10.4%; p  0.07).
The FMD at 1 month after PCI (T0) was 18.9  23.5%
in patients receiving bare-metal stents versus 11.0  10.2%
in patients treated with drug-eluting stents (p  0.25).
hsCRP levels. The hsCRP levels were lower in patients
g/day 75 Followed by 150 mg/day
(n  25) p Value
65.6 10.9 0.07
21 (84) 1.00
9 (36) 0.77
22 (88) 1.00
21 (84) 1.00
28.8 4.2 0.23
8 (32) 0.39
13 (52) 1.00
8 (32) 0.77
55.5 5.6 0.34
0.9 0.29 0.32
12 (48) 0.77
6 (24) 0.72
16 (64) 1.00
25 (100) —
25 (100) —
— —
dial infarction.75 m
5)
.3
)
)
)
)
4.6
)
)
)
.4
.19
)
)
)
0)
0)receiving the 150-mg/day regimen (3.6 3.0 mg/l vs. 7.0
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t
r
h
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hsCRP values from baseline were significantly attenuated
(3.3  7.0 mg/l vs. 0.2  5.1 mg/l; p  0.007).
Percentage of patients with hsCRP levels 3 mg/l tended
to be lower among those treated with the high clopidogrel
dose (46% vs. 64% in the standard dose arm, p  0.07; 95%
confidence interval: 0% to 29%) (Figs. 2 and 3).
Variations of PRU, hsCRP, FMD, and NMD at different
time points during the study period. From study points T-0
to T-1 (Fig. 4), platelet reactivity, hsCRP, and NMD values
remained essentially unchanged in the 75 mg arm (p  0.16),
hereas FMD values slightly decreased (p 0.08); conversely,
in patients initially allocated to the high maintenance regimen,
a significant decrease of PRU values (p  0.0001) and
hsCRP levels (p  0.028) was demonstrated, as well as
mprovement of endothelial function (p  0.05).
From study points T-1 to T-2, switching from standard
o high maintenance dose was associated with significant
eduction of platelet reactivity (p  0.0001), attenuation of
sCRP levels (p  0.004), FMD increase (p  0.048), and
a trend toward improved NMD (p  0.10); switching from
the 150 mg to the 75 mg regimen resulted in significant
PRU elevation (p  0.002) and FMD worsening (p 
0.001), whereas hsCRP tended to increase (p  0.12) and
NMD to decrease (p  0.09).
Both hsCRP and FMD values were weakly correlated to
PRU values (r  0.21, p  0.043 and r  0.18, p  0.06,
respectively).
Discussion
The prospective, randomized ARMYDA-150 study dem-
onstrates that, compared with the standard 75-mg daily
dose, use of 150-mg/day clopidogrel maintenance regimen
is associated with a higher degree of platelet inhibition and
reduction of low-responders, as well as with significant
improvement of endothelial function and enhanced anti-
inflammatory effects. The standard 75-mg/day clopidogrel
Outcome Measures in the 2 ArmsTable 2 Outcome Measures in the 2 Arms
High Dose 1
Platelet reactivity
PRU value 141
PRU inhibition from baseline, % 50
Patients with PRU 240, % 12
Brachial artery reactivity, %
FDM 16.9
Patients with FMD 7% 16
NMD 18.2
Inflammation
hsCRP, mg/l 3.6
Delta hsCRP, mg/l 3.3
Patients with hsCRP 3 mg/l, % 46
Outcome measures of P2Y12 reaction units (PRU), flow-mediated
C-reactive protein (hsCRP) are shown in the 2 arms. Cumulative data
mg/day versus 150 mg/day clopidogrel are reported.maintenance dose has been derived from pharmacodynamicstudies, as it provides on average a degree of platelet
inhibition equivalent to that obtained with a 500-mg daily
dose of ticlopidine (26), but it may nevertheless be inade-
quate in some patients undergoing PCI (8). Antiplatelet
effects of clopidogrel may be improved by doubling the
chronic dose from 75 to 150 mg/day: aggregometry studies
demonstrated that the higher maintenance regimen pro-
vides stronger platelet inhibition and reduces incidence of
low-responders (11,25,27–30). Such protocols were per-
formed on specific subgroups of patients, such as patients
with diabetes mellitus (29) or patients receiving PCI for an
acute myocardial infarction (27); moreover, in those studies,
serial pre- and post-treatment platelet function evaluations
were not systematically done (11,28,30) and different load-
ing regimens of clopidogrel were used (25). The ARMYDA-
150 study was performed on a consecutive series of unselected
patients who had received the same clopidogrel loading regi-
men (600 mg) at the time of PCI and were randomly allocated
to the 2 clopidogrel doses 30 days after intervention; of note,
our protocol excluded concomitant factors or therapies poten-
tially interfering with antiplatelet response to clopidogrel (cig-
arette smoking, lipophilic statins, proton-pump inhibitors).
Both antiplatelet and pleiotropic effects of the 2 maintenance
doses were systematically evaluated before and after time
periods of 1 month, and the cross-over allowed to have an
internal control within the study population. Results of the
point-of-care platelet function assay demonstrated in the
150-mg/day clopidogrel arm a significantly higher platelet
inhibition from estimated baseline (50% vs. 31% in the
75-mg group), as well as a 20% absolute reduction of low-
responders using a clinically-driven threshold of platelet
reactivity (PRU 240).
Experimental studies in the isolated pig heart showed that
clopidogrel administration is associated with an increase in
endothelium-dependent coronary vasodilation, and it is able to
cause nitric oxide release from cultured endothelial cells (31);
moreover, a randomized study (15) of patients with stable
/day Standard Dose 75 mg/day p Value
198 71 0.004
31 20 0.0001
32 0.001
7.9 7.5 0.0001
58 0.0003
12.0 10.4 0.07
7.0 8.6 0.016
0.2 5.1 0.007
64 0.07
(FMD), nitroglycerin-mediated dilation (NMD), and high-sensitivity
nd T2 on the overall population after 1 month of treatment with 7550 mg
73
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High Versus Standard Clopidogrel Maintenance in PCI February 15, 2011:771–8clopidogrel loading doses on endothelial function, showing
that a 600-mg regimen causes a higher and faster (2 h)
improvement of flow-mediated brachial artery dilation than
the 300-mg regimen does; this effect paralleled the antiplatelet
effect of the drug, but was not accompanied by changes in
platelet oxidative stress and nitric oxide bioavailability. To date,
no study evaluated in a randomized protocol the chronic effects
of different clopidogrel maintenance doses on endothelial
function. The ARMYDA-150 study demonstrated a dose-
dependent effect of clopidogrel on brachial artery reactivity: the
150-mg/day regimen was associated with significant improve-
ment in FMD and a 42% absolute reduction of impaired
brachial artery reactivity (FMD 7%) compared with the
75-mg daily dose. Our results might have an impact on
ytivitcaeRyretrAlaihcarB
ytivitcaeRteletalP
FMD
(%)
PRU
240 
75 mg 150 mg
400
300
200
100
150
250
350
50
75 mg 150 mg
7%
5
10
15
20
25
30
75 mg 150 mg
HS-CRP
(mg/L)
3 mg/L5
10
15
20
25
30
35
40
Inflammation
P=0.001
P=0.0003
P=0.07
Figure 2 Individual Data of Platelet Reactivity, Brachial Artery
Reactivity, and hsCRP in the 2 Randomization Arms
Cumulative data of T1 and T2 on the overall population after 1 month of treatment
with 75 mg/day versus 150 mg/day clopidogrel are reported. Abbreviations as in
Figure 1.practice patterns in light of recent data showing that endothe-lial dysfunction after PCI is associated with a higher risk of
in-stent restenosis in patients undergoing bare-metal stent
implantation (23), and may theoretically predispose to stent
thrombosis after drug-eluting stent implantation. Further
studies are needed to evaluate whether improvement of endo-
thelial function by high-dose clopidogrel is linked to drug-
induced inhibition of platelet activation, with decreased release
by platelets of vasoactive mediators that may contribute to
endothelial dysfunction, or whether it is due to a direct
interaction with endothelial P2Y12 receptors (32). Indeed, in
ur study, brachial artery vasodilation properties independent
f endothelial nitric oxide production were also improved with
he higher regimen.
Anti-inflammatory effects of clopidogrel have been pre-
iously described in the setting of PCI, with attenuation of
ost-procedural raise of CRP levels (13); clopidogrel with-
rawal was followed by significant increase of CRP levels in
iabetic patients with coronary artery disease (14), whereas
single randomized study on patients with stable angina
ailed to demonstrate a significant reduction of CRP values
n patients chronically receiving 75 mg/day clopidogrel (33).
oreover, in the CHARISMA (Clopidogrel for High
therothrombotic Risk and Ischemic Stabilization, Man-
gement, and Avoidance) trial (34) a 75 mg daily mainte-
ance dose did not affect markers of inflammation. Recently,
50 mg/day clopidogrel after primary PCI was associated,
ompared with the standard 75 mg/day regimen, with a more
apid decline of CRP levels after the infarction (27).
The ARMYDA-150 study indicates that the higher clopi-
ogrel maintenance regimen significantly attenuates hsCRP
evels after PCI and is associated with 18% absolute reduction
f persistently elevated (3 mg/l) hsCRP levels. These results
hould be evaluated in light of previous data indicating that
levated CRP levels increase the risk of future cardiac events
fter PCI, and reduction of such levels may favorably impact
rognosis (35). Whether the anti-inflammatory benefit of
igh-dose clopidogrel reflects a direct anti-inflammatory effect
r whether it is a consequence of the higher platelet inhibition
HS-CRP >3 mg/L
FMD <7%
PRU ≥240
-80%           -60%          -40%           -20%             0
Figure 3 Difference in Percentage of Patients With PRU
>240, FMD <7%, and hsCRP >3 mg/l
High clopidogrel dose compared with standard dose: mean and 95% confi-
dence interval are reported. Abbreviations as in Figure 1.
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our study, both CRP levels and FMD values were weakly
correlated to residual platelet reactivity on clopidogrel.
The protocol of the ARMYDA-150 study allowed us to
consistently demonstrate significantly higher platelet inhi-
bition, better FMD, and CRP reduction after changing
from the 75- to the 150-mg clopidogrel dose, and, con-
versely, increase of platelet reactivity, impairment of endo-
thelial function, and enhancement of inflammatory status
after switching back from a 150- to a 75-mg maintenance
regimen. At the beginning of the study, those parameters
were similar in the 2 arms (Fig. 4), whereas at T1 (when 1
arm had received the high dose for 1 month), they were
different. At T2, there were no significant differences in
those parameters between the 2 arms: thus, it is possible that
the beneficial effects of the 150-mg dose do not wane
completely after 1 month; in particular, FMD and CRP
levels did not come back to baseline values after 1 month on
75 mg clopidogrel. However, the main results of the study
regarding the comparison between 75- and 150-mg daily
dose derive from a paired analysis of all individual data.
Those results may contribute to further illustrate mech-
anisms of clinical benefit recently observed with the 150-mg
versus the 75-mg clopidogrel maintenance regimen in PCI
patients; in particular, in the CURRENT-OASIS 7 (Clopi-
dogrel and Aspirin Optimal Dose Usage to Reduce Recur-
rent Events–Seventh Organization to Assess Strategies in
Figure 4 Variations of PRU, FMD, NMD, and hsCRP at Differen
Squares indicate patients initially randomized to 75 mg/day clopidogrel; trianglesIschemic Syndromes) trial (36), high clopidogrel doses(600-mg loading plus 150 mg/day for 7 days), compared
with 300-mg load followed by 75-mg/day regimen, signif-
icantly reduced 30-day incidence of stent thrombosis and
myocardial infarction in the subgroup of patients with ACS
undergoing PCI.
Conclusions
Our study was not powered or intended to evaluate inci-
dence of clinical events (death, myocardial infarction, stent
thrombosis, repeat revascularization) or bleeding complica-
tions in the 2 arms. However, ARMYDA-150 indicates
that a high clopidogrel maintenance dose, in addition to a
stronger antiplatelet effect, is associated with significant
“pleiotropic” effects, which may potentially translate into a
significant clinical benefit for patients undergoing PCI.
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